Industrials · Aerospace & Defense · Synthos Deep Dive · 2026-07-03
| Verdict | Hold — systematic Synthos tier |
| Price (2026-07-03) | $549.01 · market cap ~$78B |
| Synthos scores (0–10) | Downside Risk 4 · Growth Quality 5 · Exponential Potential 2 |
| Synthos fair value (base case) | ~$560 → +2% · full range $420 (bear) – $640 (bull) |
| Street consensus | $730.58 (high $815 / low $580; 20 Buy · 14 Hold · 1 Sell) — context, not our anchor; the Street is far more bullish than we are |
| Valuation | 17× trailing EPS · 20× FY26E · 18× FY27E · 15× FY30E · EV/S 2.2× · EV/EBITDA 12× |
| Exponential Potential | 2/10 · Low — ~5% forward revenue & EPS CAGR, roughly stable (not accelerating); a large but slow-turning defense TAM |
| Technicals | Downtrend — $549, −28% off the 52-wk high, below 50/200-DMA, RSI 49, +9% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices in KB, 0 reconciled claims; call rests on the numbers |
| Position sizing | Tactical/satellite, ~1–3% — a valuation-plus-catalyst trade, not a flagship core |
| Next catalyst | 2026-07-21 Q2'26 earnings (Street EPS $6.81, revenue ~$10.8B) |
| Single biggest risk | Fixed-price development programs (B-21, Sentinel) re-provisioning losses and compressing margins |
One-line thesis. A blue-chip defense prime trading at a reasonable ~17× trailing / 12× EV-EBITDA after a ~28% drawdown, with a negative beta, a $96B backlog, and reaffirmed 2026 guidance — but the growth is genuinely modest (~5% EPS CAGR) and the fixed-price B-21/Sentinel programs have already burned shareholders once; we see it as a fairly-valued defensive worth a tactical position, not the Street's $730 story.
Northrop Grumman builds big-ticket military hardware for the U.S. government and its allies: the B-21 stealth bomber, the Sentinel intercontinental missile, satellites, radars, and missile-defense systems. It is one of a handful of "primes" that the Pentagon literally cannot do without.
The stock has fallen about 28% from its high, so it is no longer expensive — you pay about 17 dollars for every dollar of yearly profit, which is reasonable for a stable, boring, essential business. The catch: this company grows slowly — roughly 5% a year — and it has been burned before by fixed-price contracts where it agreed to build something for a set fee and it cost more than expected (it took a big write-off on the B-21 bomber in 2025).
Our verdict is Buy — Tactical: worth owning as a small, defensive position that could recover toward fair value, but not a fast grower and not a large "core" holding.
Here's what our three scores mean in everyday terms:
The one big worry: the giant fixed-price programs (the B-21 bomber, the Sentinel missile) could again cost more to build than the contracts pay, forcing another loss and denting the profit that makes the stock cheap.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 56.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = NOC · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Northrop Grumman (NYSE: NOC) is a ~97,000-employee, Falls Church, Virginia-headquartered global aerospace and defense prime, founded in 1939. Its customer is overwhelmingly the U.S. government (military and intelligence), with allied foreign military sales as a secondary channel. Fiscal year ends December 31. The business runs in four segments:
Revenue mix by segment (FY2025, from filings):
Revenue by geography (FY2024, latest full split in filings): United States $36.0B (~88%), Europe $2.84B, Asia-Pacific $1.55B, other $0.61B. FMP's FY2025 geographic file lists only Europe $3.29B and Asia-Pacific $1.92B; the concentration in the U.S. government is the defining structural feature — a source of backlog stability and, simultaneously, single-customer/budget-cycle risk (§11).
The forward story is two flagship programs: the B-21 Raider (next-gen strategic bomber, now in production ramp) and Sentinel (the ground-based ICBM replacement). Both are in the earnings release below as management's own headline: it reached agreements with the Air Force to increase B-21 production capacity and accelerate Sentinel initial operating capability (§9).
There is no expert coverage for NOC in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, top = []. No podcast, fund-manager, or analyst voice in our distilled panel has spoken on Northrop Grumman in a way we can reconcile to a claim_id.
Per House Standard, that means this verdict is fundamentals- and quant-driven only — built from FMP financials, analyst estimates, the technical block, and management's own SEC-filed guidance. We do not manufacture conviction to fill the gap: there are no claim IDs to cite because none exist. Where you see the Street's consensus ($730.58, 20 Buy / 14 Hold / 1 Sell) below, treat it as sell-side context, not Synthos conviction.
Honest read: the absence of KB coverage is itself information — NOC is not a name the exponential-growth / next-exponential panel Synthos tracks tends to feature, which is consistent with our own Low Exponential score. A defense prime is a stability holding, not a thesis stock.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Reasonable 17× TTM / 12× EV-EBITDA after a 28% drawdown, negative beta (−0.12) → defensive. Offsets: net-debt/EBITDA ~1.9×, and fixed-price development programs (B-21, Sentinel) that have already produced loss provisions. |
| Growth Quality | 5 · Moderate | ~5% forward revenue & EPS CAGR, stable ~11% operating margin, 28% ROE but only ~10% ROIC (goodwill-heavy). Durable moat and a $96B backlog — quality, but slow. |
| Exponential Potential | 2 · Low | Mid-single-digit growth, roughly stable (not accelerating). Defense TAM is large but turns slowly; a $78B cap in a program-funded market does not multibag. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Defense-spend supercycle; B-21 ramps at target margin, Sentinel restructured favorably; segment margins recover toward 11–12%. FY27E EPS beats to ~$32 (vs $30.2 cons); multiple re-rates to ~20×. | ~$640 (+17%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$30.2; a stable ~5% compounder holds a ~18.5× multiple (near its own history). | ~$560 (+2%) |
| Bear | A new fixed-price loss provision (B-21/Sentinel) or a budget-continuing-resolution air-pocket; FY27E EPS misses to ~$28; multiple de-rates to ~15×. | ~$420 (−23%) |
Synthos fair value = the base case, ~$560 (+2%), with the full $420–$640 span as the honest range. This anchor sits well below the Street's $730.58 consensus — the sell side is modeling a fuller multiple and stronger margin recovery than we will underwrite given the program-loss track record. Our bull ($640) still does not reach the Street's mid-point, and even the Street's low ($580) is above our base. We are the cautious voice here on purpose. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). NOC is a slow, durable compounder with essentially no exponential character:
Exponential Potential: Low (2/10). Own NOC for defensive stability, a ~1.7% dividend, buybacks, and negative-beta ballast — not for a fast multibagger. This honest framing is why NOC, if held at all, belongs in a satellite/defensive sleeve, not the exponential flagship.
After the drawdown, NOC is not expensive: 17× trailing EPS, 2.2× sales, 12× EV/EBITDA, ~4.2% FCF yield, ~1.7% dividend yield. On live consensus the forward P/E is 20× (FY26E) → 18× (FY27E) → 15× (FY30E) — but note the multiple compresses mainly because EPS grows ~5%/yr, not because of a demand surge. This is a fairly-valued defensive, not a bargain and not a growth story.
The tension is with the Street: consensus price target $730.58 (high $815, low $580, median $751) implies ~24× FY27E — a full re-rate plus margin recovery. Our base case (~$560, ~18.5× FY27E) declines to underwrite that premium given (a) the fixed-price loss history and (b) mid-single-digit growth that does not justify a 24× multiple. We would rather be paid to wait: buy the defensive/negative-beta ballast and the buyback-driven per-share growth at a reasonable price, and treat any re-rate toward the Street as upside optionality, not the base case. Not a value trap, not a growth buy — a fairly-priced defensive with a catalyst path.
NOC's moat is structural: (1) it is one of a tiny oligopoly of U.S. defense primes cleared and capitalized to build strategic-scale systems (bombers, ICBMs, space/missile-defense) — the barriers to entry (security clearances, capital, program heritage, sole-source franchises like the B-21 and Sentinel) are the entire point; (2) a $96B backlog ($9.8B Q1'26 net awards) provides multi-year revenue visibility; (3) switching costs are effectively infinite on sole-source strategic programs. The offset: the customer is a single, budget-constrained buyer with strong pricing leverage on fixed-price development work — which is exactly where the margin risk lives.
Peer set (FMP-supplied; market cap): the true defense comps are Lockheed Martin $126B, General Dynamics $101B, L3Harris $56B; the file also lists broader industrials — Howmet $108B, Waste Management $93B, 3M $84B, Emerson $78B, Illinois Tool Works $78B, UPS $83B, TransDigm $75B. Against LMT and GD, NOC carries a similar mid-teens multiple; its differentiator is the concentrated bet on two strategic flagship programs (B-21, Sentinel), which is both its upside lever and its concentration risk.
Thesis tripwires (what would change the call): a new material fixed-price loss provision; segment margin sliding below ~10%; book-to-bill dropping below 1×; or a budget air-pocket. A clean margin-recovery trajectory plus reclaiming the 50/200-DMA would upgrade the technical setup.
Buy — Tactical. After a ~28% drawdown NOC is a fairly-valued (17× TTM / 12× EV-EBITDA), negative-beta defense prime with a $96B backlog, reaffirmed 2026 guidance, and two catalyst-rich flagship programs (B-21 capacity up, Sentinel accelerating). That is enough for a tactical, valuation-plus-catalyst position — but not more: growth is only ~5%, the fixed-price programs have burned holders once, the technicals are still weak, and there is no expert conviction in our KB to corroborate. Our base fair value (~$560) sits well below the Street's $730.58, so we are explicitly the cautious voice.
claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation) and none is asserted here.